$IPSC
Century Therapeutics, Inc. Stock $ipsc

$ipsc Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022003867 Filed on March 17, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.177M	$19.24M	$9.495M
YoY Change	-34.94%	102.58%
% of Gross Profit
Research & Development	$21.80M	$75.65M	$12.44M
YoY Change	75.21%	90.64%
% of Gross Profit
Depreciation & Amortization	$1.051M	$3.748M	$920.0K
YoY Change	14.24%	167.33%
% of Gross Profit
Operating Expenses	$27.97M	$94.88M	$49.18M
YoY Change	-43.12%	76.04%
Operating Profit		-$94.88M
YoY Change		76.04%
Interest Expense	-$321.0K	$1.275M	-$381.0K
YoY Change	-15.75%	234.65%
% of Operating Profit
Other Income/Expense, Net	$143.0K	-$898.0K	$704.0K
YoY Change	-79.69%	-378.02%
Pretax Income	-$28.15M	-$95.78M	-$53.58M
YoY Change	-47.45%	78.78%
Income Tax	$43.00K	$43.00K
% Of Pretax Income
Net Earnings	-$28.19M	-$95.82M	-$53.58M
YoY Change	-47.37%	78.86%
Net Earnings / Revenue
Basic Earnings Per Share		-$2.96
Diluted Earnings Per Share	-$512.1K	-$2.96	-$7.161M
COMMON SHARES
Basic Shares Outstanding	54.64M	32.39M
Diluted Shares Outstanding		32.39M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$222.9M	$222.9M
YoY Change		194.22%
Cash & Equivalents	$56.45M	$56.45M	$27.21M
Short-Term Investments	$166.4M	$166.4M
Other Short-Term Assets	$250.0K	$5.275M	$256.0K
YoY Change	-2.34%	73.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$228.2M	$228.2M	$78.80M
YoY Change	189.55%	189.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.97M	$69.82M	$15.39M
YoY Change	276.78%	181.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$135.9M	$135.9M
YoY Change		12807.31%
Other Assets	$3.486M	$3.486M
YoY Change		62.21%
Total Long-Term Assets	$209.2M	$209.2M	$27.98M
YoY Change	647.78%	647.78%
TOTAL ASSETS
Total Short-Term Assets	$228.2M	$228.2M	$78.80M
Total Long-Term Assets	$209.2M	$209.2M	$27.98M
Total Assets	$437.4M	$437.4M	$106.8M
YoY Change	309.62%	309.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.596M	$7.596M	$8.082M
YoY Change	-6.01%	-6.01%
Accrued Expenses	$6.040M	$6.040M
YoY Change		49.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.039M	$1.039M
YoY Change
Total Short-Term Liabilities	$15.66M	$15.66M	$12.11M
YoY Change	29.25%	29.25%
LONG-TERM LIABILITIES
Long-Term Debt	$8.903M	$8.903M	$9.636M
YoY Change	-7.61%	-7.61%
Other Long-Term Liabilities	$16.58M	$16.58M
YoY Change		41.96%
Total Long-Term Liabilities	$8.903M	$25.48M	$9.636M
YoY Change	-7.61%	19.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.66M	$15.66M	$12.11M
Total Long-Term Liabilities	$8.903M	$25.48M	$9.636M
Total Liabilities	$41.14M	$41.14M	$33.43M
YoY Change	23.07%	23.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$388.2M		-$292.3M
YoY Change	32.78%
Common Stock	$785.1M		$217.8M
YoY Change	260.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$396.2M	$396.2M	-$106.4M
YoY Change
Total Liabilities & Shareholders Equity	$437.4M	$437.4M	$106.8M
YoY Change	309.62%	309.62%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$28.19M	-$95.82M	-$53.58M
YoY Change	-47.37%	78.86%
Depreciation, Depletion And Amortization	$1.051M	$3.748M	$920.0K
YoY Change	14.24%	167.33%
Cash From Operating Activities	-$24.35M	-$89.00M	-$22.44M
YoY Change	8.49%	115.66%
INVESTING ACTIVITIES
Capital Expenditures	-$16.72M	$44.97M	-$6.410M
YoY Change	160.86%	357.71%
Acquisitions
YoY Change
Other Investing Activities	-$3.881M	-$253.4M	-$13.90M
YoY Change	-72.07%	2986.09%
Cash From Investing Activities	-$20.60M	-$298.3M	-$20.31M
YoY Change	1.46%	1210.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$213.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	106.0K	417.8M	47.70M
YoY Change	-99.78%	776.02%
NET CHANGE
Cash From Operating Activities	-24.35M	-89.00M	-22.44M
Cash From Investing Activities	-20.60M	-298.3M	-20.31M
Cash From Financing Activities	106.0K	417.8M	47.70M
Net Change In Cash	-44.85M	30.43M	4.951M
YoY Change	-1005.82%	-286.3%
FREE CASH FLOW
Cash From Operating Activities	-$24.35M	-$89.00M	-$22.44M
Capital Expenditures	-$16.72M	$44.97M	-$6.410M
Free Cash Flow	-$7.630M	-$134.0M	-$16.03M
YoY Change	-52.42%	162.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.centurytx.com/20211231#AccruedExpensesAndOtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.centurytx.com/20211231#AccruedExpensesAndOtherLiabilitiesCurrent
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32392554
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7481861
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.96
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.16
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.96
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.16
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32392554
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7481861
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001850119
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89002000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55005523
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7481861
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36510
CY2021	dei	Entity Registrant Name EntityRegistrantName	Century Therapeutics, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2040295
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	3675 Market Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Philadelphia
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19104
CY2021	dei	City Area Code CityAreaCode	267
CY2021	us-gaap	Depreciation Depreciation	3748000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	213000
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	1053000
CY2021	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56445000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27211000
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1549000
CY2021	dei	Local Phone Number LocalPhoneNumber	817-5790
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	166434000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	48542000
CY2021Q4	ipsc	Escrow Deposits Current EscrowDepositsCurrent	502000
CY2020Q4	ipsc	Escrow Deposits Current EscrowDepositsCurrent	783000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4773000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2261000
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	909000
CY2021Q4	us-gaap	Assets Assets	437375000
CY2021	dei	Trading Symbol TradingSymbol	IPSC
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	669088584
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58819215
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021Q4	us-gaap	Assets Current AssetsCurrent	228154000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	78797000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57967000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15385000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11854000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9392000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1717000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	517000
CY2021Q4	ipsc	Escrow Deposits Noncurrent EscrowDepositsNoncurrent	220000
CY2020Q4	ipsc	Escrow Deposits Noncurrent EscrowDepositsNoncurrent	723000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	135914000
CY2020Q4	us-gaap	Assets Assets	106776000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7596000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8082000
CY2021Q4	ipsc	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	6040000
CY2020Q4	ipsc	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	4030000
CY2021Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	980000
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1039000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15655000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12112000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14559000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11679000
CY2021Q4	ipsc	Deposit Liability Noncurrent DepositLiabilityNoncurrent	2020000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8903000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9636000
CY2021Q4	us-gaap	Liabilities Liabilities	41137000
CY2020Q4	us-gaap	Liabilities Liabilities	33427000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125236190
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55005523
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7481861
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	785049000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	217832000
CY2020Q4	ipsc	Common Units Share Subscribed But Unissued Subscriptions Receivable CommonUnitsShareSubscribedButUnissuedSubscriptionsReceivable	-31900000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388166000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292342000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-650000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	396238000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-106412000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	437375000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106776000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75648000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39681000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19235000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9495000
CY2020	ipsc	Write Off Of In Process Research And Development Asset WriteOffOfInProcessResearchAndDevelopmentAsset	4722000
CY2021	us-gaap	Operating Expenses OperatingExpenses	94883000
CY2020	us-gaap	Operating Expenses OperatingExpenses	53898000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-94883000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-53898000
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1275000
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	381000
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	377000
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	704000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-898000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	323000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95781000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53575000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95824000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53575000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.96
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.16
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32392554
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7481861
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95824000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53575000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-615000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	8000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-32000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96471000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53575000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-91859000
CY2020	ipsc	Receipt Of Subscription Receivable ReceiptOfSubscriptionReceivable	38100000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	8000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	46000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-8000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	876000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53575000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-106412000
CY2021	ipsc	Receipt Of Subscription Receivable ReceiptOfSubscriptionReceivable	31900000
CY2021	ipsc	Net Assets Contributed Resulting From Merger NetAssetsContributedResultingFromMerger	1061000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	339388000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	221402000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	213000
CY2021	ipsc	Stock Issued During Period Value Vesting Of Early Exercise Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseStockOptions	426000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	69000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-615000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-32000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4662000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95824000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	396238000
CY2021	us-gaap	Profit Loss ProfitLoss	-95824000
CY2020	us-gaap	Profit Loss ProfitLoss	-53575000
CY2020	ipsc	Write Off Of In Process Research And Development Asset WriteOffOfInProcessResearchAndDevelopmentAsset	4722000
CY2020	us-gaap	Depreciation Depreciation	1402000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	306000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	92000
CY2021	ipsc	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	834000
CY2020	ipsc	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	352000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4662000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	876000
CY2021	ipsc	Warrants Issued For Services WarrantsIssuedForServices	69000
CY2021	ipsc	Increase Decrease In Escrow Deposit IncreaseDecreaseInEscrowDeposit	-784000
CY2020	ipsc	Increase Decrease In Escrow Deposit IncreaseDecreaseInEscrowDeposit	1506000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3182000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	203000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-41000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	2175000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1848000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2062000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1490000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2334000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89002000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41269000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44970000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9825000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	330034000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49860000
CY2020	ipsc	Payments To Acquire Assets Net Of Cash Acquired PaymentsToAcquireAssetsNetOfCashAcquired	4722000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	76666000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41650000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-298338000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22757000
CY2020	ipsc	Proceeds From Issuance Of Long Term Debt And Warrants Net ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet	9734000
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	144000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	221402000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2305000
CY2021	ipsc	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	31900000
CY2020	ipsc	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	38100000
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	159628000
CY2021	ipsc	Cash Contributed Resulting From Merger CashContributedResultingFromMerger	2326000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	417774000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47690000
CY2021	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	30434000
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16336000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27728000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44064000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58162000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27728000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	969000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	207000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	14000
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	339388000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1360000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4472000
CY2021Q2	ipsc	Redeemable Convertible Preferred Stock Convertible Shares Issuable RedeemableConvertiblePreferredStockConvertibleSharesIssuable	34126528
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95824000
CY2021Q4	ipsc	Cash And Cash Equivalents Short And Long Term Investments CashAndCashEquivalentsShortAndLongTermInvestments	358793000
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2.5161
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27728000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of estimates</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuations supporting stock compensation and the estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of credit risk and other risks and uncertainties</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash, cash equivalents, U.S. Treasury bills and bonds, as well as corporate bonds. Cash and cash equivalents, as well as short and long-term investments include a checking account and asset management accounts held by a limited number of financial institutions. At times, such deposits may be in excess of insured limits. As of December 31, 2021 and 2020, the Company has not experienced any losses on its deposits of cash and cash equivalents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of its products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships, and dependence on key individuals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed, or if the Company was unable to maintain clearance, it could have a material adverse impact on the Company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a “Public Health Emergency of International Concern,” which continues to spread throughout the world and has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The COVID-<span style="white-space:pre-wrap;">19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. Vaccines were introduced late in the fourth quarter of 2020 and became widely available by the end of the first quarter of 2021. While the vaccines have proven effective in reducing the severity and mortality of COVID-19 including the variants that have evolved to date, the overall vaccination rate in the United States may not have reached the level required for herd immunity. Certain variants of COVID-19, such as the delta and omicron variants, are proving to be more easily spread than earlier variants. The incomplete vaccination rate, and the emergence of new variants which could prove resistant to existing vaccines could again result in major disruptions to businesses and markets worldwide. The Company continues to monitor the impact of the COVID-19 outbreak closely. The extent to which the COVID-19 outbreak will impact its operations or financial results is uncertain.</span></p>
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16966000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5329000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1717000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	517000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56445000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27211000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1717000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	517000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58162000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1581000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57967000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15385000
CY2021	us-gaap	Depreciation Depreciation	3748000
CY2020	us-gaap	Depreciation Depreciation	1402000
CY2021	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	355230000
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	24284000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1053000
CY2021Q4	us-gaap	Employee Stock Ownership Plan Esop Fair Value Of Shares Subject To Repurchase Obligation EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation	3000000
CY2020Q4	us-gaap	Employee Stock Ownership Plan Esop Fair Value Of Shares Subject To Repurchase Obligation EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation	0
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	73879000
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	302950000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	602000
CY2021Q4	ipsc	Common Stock Shares Legally Outstanding CommonStockSharesLegallyOutstanding	56633898
CY2020Q4	ipsc	Common Stock Shares Legally Outstanding CommonStockSharesLegallyOutstanding	8865992
CY2021	ipsc	Stock Issued During Period Shares Stock Options Exercised Unvested StockIssuedDuringPeriodSharesStockOptionsExercisedUnvested	946586
CY2020	ipsc	Stock Issued During Period Shares Stock Options Exercised Unvested StockIssuedDuringPeriodSharesStockOptionsExercisedUnvested	330629
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	681789
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1053502
CY2021Q4	ipsc	Common Stock Shares Issued And Outstanding CommonStockSharesIssuedAndOutstanding	55005523
CY2020Q4	ipsc	Common Stock Shares Issued And Outstanding CommonStockSharesIssuedAndOutstanding	7481861
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	302348000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	49595000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14559000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11679000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15174000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11919000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34262000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7372000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	52882000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	302348000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	49587000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	49595000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	166434000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	48542000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	135914000
CY2021Q4	ipsc	Prepaid Research And Development PrepaidResearchAndDevelopment	210000
CY2020Q4	ipsc	Prepaid Research And Development PrepaidResearchAndDevelopment	97000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1606000
CY2021Q4	ipsc	Prepaid Software Licenses And Other PrepaidSoftwareLicensesAndOther	2033000
CY2020Q4	ipsc	Prepaid Software Licenses And Other PrepaidSoftwareLicensesAndOther	760000
CY2021Q4	ipsc	Prepaid Miscellaneous Receivables PrepaidMiscellaneousReceivables	250000
CY2020Q4	ipsc	Prepaid Miscellaneous Receivables PrepaidMiscellaneousReceivables	908000
CY2021Q4	ipsc	Prepaid Warranties PrepaidWarranties	424000
CY2020Q4	ipsc	Prepaid Warranties PrepaidWarranties	240000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	250000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	256000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4773000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2261000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2753000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	10395000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-53602000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	178000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	27000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95824000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53575000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	63296000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4445000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3132000
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	82000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	82000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	796000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	524000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	615000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240000
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	102000
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	52000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6040000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4030000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	615000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000
CY2021Q4	ipsc	Debt Instrument End Of Term Fee DebtInstrumentEndOfTermFee	-395000
CY2020Q4	ipsc	Debt Instrument End Of Term Fee DebtInstrumentEndOfTermFee	-395000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	25000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	43000
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	428000
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	716000
CY2021Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	9942000
CY2020Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	9636000
CY2020Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	16112
CY2020Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P10Y
CY2020Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.96
CY2020Q3	ipsc	Class Of Warrant Or Right Fair Value ClassOfWarrantOrRightFairValue	46000
CY2020Q3	ipsc	Minimum Percentage Of Warrants And Rights To Be Issued Of Aggregate Amount Funded MinimumPercentageOfWarrantsAndRightsToBeIssuedOfAggregateAmountFunded	0.0225
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	969000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	289000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	306000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	92000
CY2021	us-gaap	Interest Expense InterestExpense	1275000
CY2020	us-gaap	Interest Expense InterestExpense	381000
CY2020	us-gaap	Lease Cost LeaseCost	3418000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2723000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2689000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1039000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	6603000
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125236190
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	85865789
CY2021Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q2	ipsc	Redeemable Convertible Preferred Stock Convertible Shares Issuable RedeemableConvertiblePreferredStockConvertibleSharesIssuable	34126528
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1549000
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	909000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2256000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	935000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	709000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	131000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2628000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2352000
CY2021	us-gaap	Lease Cost LeaseCost	5593000
CY2021	ipsc	Schedule Of Supplemental Balance Sheet Information Related To Leases ScheduleOfSupplementalBalanceSheetInformationRelatedToLeases	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">As of </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">As of </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:33.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:33.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Location in Balance Sheet</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:33.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:33.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:33.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_1KgKuWifUkOIr__S0cTn4A;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses and other liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:33.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:33.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr></table>
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11854000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9392000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y11M26D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2021	ipsc	Schedule Of Supplemental Cash Flow Information Related To Leases ScheduleOfSupplementalCashFlowInformationRelatedToLeases	<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13806152%;padding-left:0pt;padding-right:0pt;width:100.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;width:14.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">For the Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;width:14.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">For the Year Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:65.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:65.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:65.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:65.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for lease obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p></td></tr></table>
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	41000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2175000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3295000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9735000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2612000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2747000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2761000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	16225000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	29757000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10877000
CY2021Q4	ipsc	Lessee Tenant Incentive Receivable LesseeTenantIncentiveReceivable	3706000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15174000
CY2021Q4	ipsc	Lessee Operating Lease Lease Not Yet Commenced Number Of Leases LesseeOperatingLeaseLeaseNotYetCommencedNumberOfLeases	1
CY2021Q4	ipsc	Lessee Operating Lease Lease Not Yet Commenced Lease Liability LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability	17400000
CY2021Q4	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P10Y
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-96002000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	43000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	43000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.105
CY2021	ipsc	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.043
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	-0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.322
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.030
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28537000
CY2021Q4	ipsc	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5127000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	1530000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4211000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	729000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1500000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	41634000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3366000
CY2021Q4	ipsc	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	4006000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7372000
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95824000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53575000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32392554
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7481861
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.96
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.16
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	566033
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.41
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	876000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M9D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1520000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7338988
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	66426361
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	536000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	301000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4662000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11595000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y6M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	5237000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1053502
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.35
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	194320
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.95
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	681789
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.20

Files In Submission

Name	View Source	Status
0001558370-22-003867-index-headers.html	Edgar Link	pending
0001558370-22-003867-index.html	Edgar Link	pending
0001558370-22-003867.txt	Edgar Link	pending
0001558370-22-003867-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ipsc-20211231.xsd	Edgar Link	pending
ipsc-20211231x10k.htm	Edgar Link	pending
ipsc-20211231x10k002.jpg	Edgar Link	pending
ipsc-20211231x10k004.jpg	Edgar Link	pending
ipsc-20211231x10k005.jpg	Edgar Link	pending
ipsc-20211231x10k006.jpg	Edgar Link	pending
ipsc-20211231x10k007.jpg	Edgar Link	pending
ipsc-20211231x10k008.jpg	Edgar Link	pending
ipsc-20211231x10k009.jpg	Edgar Link	pending
ipsc-20211231x10k010.jpg	Edgar Link	pending
ipsc-20211231x10k011.jpg	Edgar Link	pending
ipsc-20211231x10k012.jpg	Edgar Link	pending
ipsc-20211231x10k013.jpg	Edgar Link	pending
ipsc-20211231x10k014.jpg	Edgar Link	pending
ipsc-20211231x10k015.jpg	Edgar Link	pending
ipsc-20211231x10k016.jpg	Edgar Link	pending
ipsc-20211231x10k017.jpg	Edgar Link	pending
ipsc-20211231x10k018.jpg	Edgar Link	pending
ipsc-20211231x10k019.jpg	Edgar Link	pending
ipsc-20211231x10k020.jpg	Edgar Link	pending
ipsc-20211231x10k021.jpg	Edgar Link	pending
ipsc-20211231x10k022.jpg	Edgar Link	pending
ipsc-20211231x10k023.jpg	Edgar Link	pending
ipsc-20211231x10k024.jpg	Edgar Link	pending
ipsc-20211231x10k025.jpg	Edgar Link	pending
ipsc-20211231x10k026.jpg	Edgar Link	pending
ipsc-20211231x10k027.jpg	Edgar Link	pending
ipsc-20211231x10k028.jpg	Edgar Link	pending
ipsc-20211231x10k029.jpg	Edgar Link	pending
ipsc-20211231x10k030.jpg	Edgar Link	pending
ipsc-20211231x10k031.jpg	Edgar Link	pending
ipsc-20211231x10k033.jpg	Edgar Link	pending
ipsc-20211231x10k034.jpg	Edgar Link	pending
ipsc-20211231x10k035.jpg	Edgar Link	pending
ipsc-20211231x10k036.jpg	Edgar Link	pending
ipsc-20211231x10k037.jpg	Edgar Link	pending
ipsc-20211231x10k038.jpg	Edgar Link	pending
ipsc-20211231x10k039.jpg	Edgar Link	pending
ipsc-20211231x10k040.jpg	Edgar Link	pending
ipsc-20211231x10k041.jpg	Edgar Link	pending
ipsc-20211231x10k042.jpg	Edgar Link	pending
ipsc-20211231x10k043.jpg	Edgar Link	pending
ipsc-20211231x10k044.jpg	Edgar Link	pending
ipsc-20211231x10k045.jpg	Edgar Link	pending
ipsc-20211231x10k046.jpg	Edgar Link	pending
ipsc-20211231x10k047.jpg	Edgar Link	pending
ipsc-20211231x10k048.jpg	Edgar Link	pending
ipsc-20211231x10k049.jpg	Edgar Link	pending
ipsc-20211231x10k_htm.xml	Edgar Link	completed
ipsc-20211231xex10d25.htm	Edgar Link	pending
ipsc-20211231xex10d31.htm	Edgar Link	pending
ipsc-20211231xex21d1.htm	Edgar Link	pending
ipsc-20211231xex23d1.htm	Edgar Link	pending
ipsc-20211231xex31d1.htm	Edgar Link	pending
ipsc-20211231xex31d2.htm	Edgar Link	pending
ipsc-20211231xex32d1.htm	Edgar Link	pending
ipsc-20211231xex32d2.htm	Edgar Link	pending
ipsc-20211231xex4d2.htm	Edgar Link	pending
ipsc-20211231_cal.xml	Edgar Link	unprocessable
ipsc-20211231_def.xml	Edgar Link	unprocessable
ipsc-20211231_lab.xml	Edgar Link	unprocessable
ipsc-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IPSC
Century Therapeutics, Inc. Stock $ipsc

2021 Q4 Form 10-K Financial Statement

#000155837022003867 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IPSC Century Therapeutics, Inc. Stock $ipsc

2021 Q4 Form 10-K Financial Statement

#000155837022003867 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IPSC
Century Therapeutics, Inc. Stock $ipsc